CTYCity Therapeutics

City Therapeutics is a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need. Our current pipeline is focused on indications with significant unmet medical need, including thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease, where we believe disease biology supports RNAi-mediated knockdown as a differentiated approach ...